Alto Neuroscience (Alto Neuroscience) Equity-to-Asset : -0.83 (As of Dec. 2023)

View and export this data going back to 2024. Start your Free Trial

What is Alto Neuroscience Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Alto Neuroscience's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $-71.67 Mil. Alto Neuroscience's Total Assets for the quarter that ended in Dec. 2023 was $86.63 Mil.

The historical rank and industry rank for Alto Neuroscience's Equity-to-Asset or its related term are showing as below:

ANRO' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.83 Med: -0.76 Max: -0.43
Current: -0.83

During the past 3 years, the highest Equity to Asset Ratio of Alto Neuroscience was -0.43. The lowest was -0.83. And the median was -0.76.

ANRO's Equity-to-Asset is ranked worse than
91.57% of 1565 companies
in the Biotechnology industry
Industry Median: 0.67 vs ANRO: -0.83

Alto Neuroscience Equity-to-Asset Historical Data

The historical data trend for Alto Neuroscience's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alto Neuroscience Equity-to-Asset Chart

Alto Neuroscience Annual Data

Trend

Dec21

Dec22

Dec23

Equity-to-Asset

-0.43

-0.76

-0.83

Alto Neuroscience Quarterly Data
	Dec21	Sep22	Dec22	Sep23	Dec23
Equity-to-Asset	-0.43	-	-0.76	-1.15	-0.83

Competitive Comparison of Alto Neuroscience's Equity-to-Asset

For the Biotechnology subindustry, Alto Neuroscience's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alto Neuroscience's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alto Neuroscience's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Alto Neuroscience's Equity-to-Asset falls into.

Alto Neuroscience Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Alto Neuroscience's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	-71.672	/	86.628
	=

Alto Neuroscience's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	-71.672	/	86.628
	=

Alto Neuroscience (NYSE:ANRO) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Alto Neuroscience Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Alto Neuroscience's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Alto Neuroscience (Alto Neuroscience) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alto Neuroscience Inc (NYSE:ANRO) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Alto Neuroscience Inc is a clinical stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and highly effective treatment options. the company currently consists of five clinical-stage assets initially targeting major depressive disorder and schizophrenia populations as identified by independent brain-based biomarkers.

Alto Neuroscience (Alto Neuroscience) Headlines

From GuruFocus

Steven Cohen's Point72 Asset Management Buys New Stake in Alto Neuroscience Inc

By GuruFocus Research • 02-08-2024